Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gyre Therapeutics, Inc. - Common Stock (NQ: GYRE )

12.85 +1.15 (+9.79%)
Streaming Delayed Price Updated: 9:52 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gyre Therapeutics, Inc. - Common Stock

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.